Comprehensive Analysis and Experimental Validation of HEPACAM2as a Potential Prognosis Biomarker and Immunotherapy Target inColorectal Cancer | Synapse
November 4, 2024
Comprehensive Analysis and Experimental Validation of HEPACAM2as a Potential Prognosis Biomarker and Immunotherapy Target inColorectal Cancer
Key Points
Key points are not available for this paper at this time.
Abstract
These findings suggest that HEPACAM2 may serve as a potential prognostic biomarker and immunotherapeutic target for CRC patients.